LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Kodu・Aktsiate loetelu・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Suletud

SektorTervishoid

9.94 1.64

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.62

Max

9.98

Põhinäitajad
By Trading Economics
Sissetulek	42M 17M
Müük	14M 169M
Aktsiakasum	0.17
Kasumimarginaal	10.237
Töötajad	499
EBITDA	54M 48M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+62.37% upside

Turustatistika
By TradingEconomics
Turukapital	678M 3B
Eelmine avamishind	8.3
Eelmine sulgemishind	9.94

Uudiste sentiment

By Acuity

100%

358 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

5.925 / 7.38 Toetus ja vastupanu

Amicus Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. dets 2025, 20:41 UTC

Tulu

Suurimad hinnamuutused turgudel

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4. dets 2025, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4. dets 2025, 17:43 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4. dets 2025, 17:01 UTC

Tulu

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4. dets 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4. dets 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4. dets 2025, 21:37 UTC

Tulu

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4. dets 2025, 21:36 UTC

Tulu

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4. dets 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4. dets 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4. dets 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4. dets 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4. dets 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. dets 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4. dets 2025, 16:33 UTC

Market Talk

Tulu

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Amicus Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

62.37% tõus

12 kuu keskmine prognoos

Keskmine 15.88 USD 62.37%

Kõrge 21 USD

Madal 11 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Amicus Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Amicus Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.925 / 7.38Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

358 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.